XGen Pharmaceuticals DJB, Inc. is excited to conclude the calendar year with another new product release!
Announcing the launch of Edaravone Injection, available in two dosages:
- 30 mg/100 mL (0.3 mg/mL), 2-pack carton (NDC#39822-4500-2)
- 60 mg/100 mL (0.6 mg/mL), single vial carton (NDC# 39822-4510-1)
Edaravone Injection, a generic therapeutic equivalent of RADICAVA® (edaravone injection), is now available, with full prescribing information available here:
“We are proud of this achievement of introducing Edaravone Injection to our portfolio as it marks our third new product launched this year”, stated Ed Vanderbeck, President of XGen Pharmaceuticals DJB. “XGen DJB’s Edaravone Injection product is positioned to be one of the first generic alternatives to market in a vial presentation as opposed to the currently available IV bag presentation. This is indicative of our continued company vision and pursuit to develop and deliver specialty pharmaceutical products to better serve the healthcare community”.
RADICAVA ® is a registered trademark of Mitsubishi Tanabe Pharma Corporation.